Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C22H15Cl2N3O and a molecular weight of approximately 408.28 g/mol. It is classified as an experimental pharmaceutical and has been referenced in drug discovery databases such as DrugBank (DB06972) and ZINC15. The structure features a pyrrolizine core substituted with dichlorophenyl and cyanobenzyl groups. According to structural biology data (PDB ID: 2O7N), this molecule has been studied in complex with the I-domain of CD11A (LFA1), suggesting it may act as an inhibitor or modulator of LFA1-mediated cell adhesion processes[4][6][7]. However, there are no approved therapeutic indications or marketed products containing this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7A-[(4-cyanophenyl)methyl]-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7A-tetrahydro-1H-pyrrolo[1,2-A]pyrrole-7-carbonitrile.